Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Male Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer
Interventions: BIOLOGICAL: HER-2/neu peptide vaccine|OTHER: laboratory biomarker analysis
Sponsor: Mayo Clinic
Collaborators: Marker Therapeutics, Inc.